MoglingBio wins further funding from Kizoo to accelerate hematopoietic stem cell and immune system rejuvenation

MoglingBioWilmington, Delaware, US – Mogling Bio, a biotech startup company developing molecules to treat age-related diseases by rejuvenating hematopoietic stem cells as well as immune cells, is thrilled to announce that Kizoo has significantly increased its investment in the company.

The underlying technology was developed over the last 15 years by the two scientific co-founders, Prof. Yi Zheng, co-director of the Cincinnati Children’s Hospital Cancer and Blood Diseases Institute and leader of the Signaling and Drug Discovery Program at the Cincinnati Children’s Research Foundation, and Prof. Dr. Hartmut Geiger, director of the Institute of Molecular Medicine at Ulm University in Germany.

This additional funding provides MoglingBio with the resources to accelerate product development towards the clinic. Kizoo recognized the company’s exceptional potential and helped to establish Mogling Bio in 2022.

Juergen Reess, CEO of Mogling Bio, acknowledged Kizoo’s continued support, saying, “This increased investment from Kizoo is a testament to the strength of our vision and the dedication of our team.

Patrick Burgermeister, Partner at Kizoo and board member at Mogling Bio expressed Kizoo´s enthusiasm for the expanded partnership, stating that “We believe that MoglingBio’s technology is groundbreaking by truly rejuvenating old stem cells – not only alleviating age-related diseases, but reversing age-related decline in immune system function”.

About Mogling Bio:

MoglingBio Inc. is developing new pharmacological approaches to rejuvenate old stem cells of the hematopoietic (blood cell formation) system. Aging causes stem cells to lose their normal structure by increased activity of the protein CDC42. This loss of structure leads to decreased production and quality of blood and immune cells. It can cause leukemia, various blood diseases, and severely weaken the immune system. Normalizing CDC42 activity can restore structure, order and functionality in those aged stem cells. Treated cells can perform their tasks again in a juvenile way, and thereby contribute to both, the rejuvenation of stem cells and the immune system.

For more information please visit:

About Kizoo:

Kizoo provides seed and follow-on financing with a focus on rejuvenation biotech. Having been entrepreneurs, VC, and mentors in both high-growth tech and biotech companies ourselves for many years with multiple exits and massive value created for the founders, Kizoo now brings this experience to the emerging field of rejuvenation biotech. We see it as a young industry that will eventually outgrow today’s largest technology markets.

As part of Michael Greve’s Forever Healthy Group, Kizoo directly supports the creation of startups turning research on the root causes of aging into therapies and services for human application. Investments include Cellvie, Cyclarity, Revel Pharmaceuticals, Elastrin Therapeutics, Mogling Bio, and others.

For more information, please visit: